IGHE and systemic lupus erythematosus: These first very encouraging results, beyond the safety of Omalizumab in SLE, underline the need for larger clinical trials evaluating the efficacy of Omalizumab in SLE and validate the anti-IgE approach as a promising new therapeutic modality in SLE (Figure 1).